Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Satellos Bioscience Inc T.MSCL

Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based a drug discovery and development company with a focus on muscle regeneration. The Company is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and... see more

TSX:MSCL - Post Discussion

View:
Post by Drambuey on Dec 29, 2021 9:25pm

.05

wow our stock is now worth .05 cents pre consolidation who are these azz clowns? Oh right, I forgot, it's the big boys shaking the tree before the big run up in the new year. I doubt it but I'm not selling for a lose,just beatching.
Comment by Itistoo on Dec 31, 2021 2:22pm
Its already a loss whether you sell or not. Sure wish I sold all my shares instead of a portion when it opened again. Didn't expect them to release absolutely nothing for 6 months after a 6 month long merger
Comment by beenthere on Jan 03, 2022 7:57am
I wonder why they would waste $10 000 a month and 60 000 shares on BND?
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities